August 2012
-
Egalet Corporation has terminated a co-promotion agreement with Septodont, the company said, and is now partnered with Valeant’s OraPharma division for co-promotion of Sprix ketorolac tromethamine nasal spray to US dentists and oral surgeons. Sprix… Read more . . .
-
Janssen Research & Development has published data from a Phase 2 study of its intranasal esketamine that demonstrate rapid improvement of symptoms in patients with treatment-resistant depression. The study was conducted from 2014-2015, and results… Read more . . .
-
By Lei Zhang, PhD, Deputy Director, Office of Research and Standards The FDA’s Center for Drug Evaluation and Research, Office of Generic Drugs (OGD), Office of Research and Standards, Division of Therapeutic Performance has made… Read more . . .
-
Generic DPI device developer Merxin has announced that its MRX003 capsule based dry powder inhaler has received CE marking certification. The inhaler, which was launched in May 2017, is designed for generic tiotropium products submitted… Read more . . .
-
Savara has submitted an investigational new drug application for Molgradex inhaled recombinant human GM-CSF for the treatment of autoimmune pulmonary alveolar proteinosis (PAP) to the FDA, the company said. In May 2017, the company said… Read more . . .
-
A citizen petition filed by Mylan on December 5, 2017 asks the FDA not to approve any ANDA for a generic version of Advair Diskus that relies on data from multiple-batch PK bioequivalence studies “unless,… Read more . . .
-
The FDA said in a Drug Safety Communication that it has approved the removal of Boxed Warnings about asthma-related deaths from ICS/LABA combination inhalers. The inhalers affected by the change are Advair Diskus, Advair HFA,… Read more . . .
-
According to Korea Biomedical Review, Korean pharmaceutical company Huons has licensed Zephirus busesonide/salmeterol, a dry powder formulation delivered using the Axahaler capsule-based inhaler, from Belgian pharmaceutical company Laboratoires SMB. Korea Biomedical Review reported that Huons… Read more . . .
-
Iconovo AB announced that it has signed an agreement with Intas Pharmaceuticals for development and licensing of a DPI for the treatment of asthma and COPD, including the dry powder formulation and a device based… Read more . . .
-
Neurodyn Cognition (NCI), a Canadian company developing an intranasal therapy for Alzheimer’s disease, has named Anthony Giovinazzo as a director and Executive Chairman. Giovinazzo was most recently President and CEO of Cynapsus Therapeutics, which was… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland